Search Results - "Gyorki, D E"

Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB–IVM1a melanoma: a randomized, open-label, phase 2 trial by Dummer, R., Gyorki, D. E., Hyngstrom, J., Berger, A. C., Conry, R., Demidov, L., Sharma, A., Treichel, S. A., Radcliffe, H., Gorski, K. S., Anderson, A., Chan, E., Faries, M., Ross, M. I.

“…Talimogene laherparepvec (T-VEC) is a herpes simplex virus type 1-based intralesional oncolytic immunotherapy approved for the treatment of unresectable…”
Get full text

Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma by Halse, H., Colebatch, A. J., Petrone, P., Henderson, M. A., Mills, J. K., Snow, H., Westwood, J. A., Sandhu, S., Raleigh, J. M., Behren, A., Cebon, J., Darcy, P. K., Kershaw, M. H., McArthur, G. A., Gyorki, D. E., Neeson, P. J.

“…A prospective study explored the heterogeneous nature of metastatic melanoma using Multiplex immunohistochemistry (IHC) and flow cytometry (FACS). Multiplex…”
Get full text

Extent of ulceration in cutaneous melanoma: is this biomarker ready for primetime? by Wilkinson, M.J., Gyorki, D.E.

“…Linked Article: Portelli et al. Br J Dermatol 2021; 184:281–288…”
Get full text

Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA by Tan, L., Sandhu, S., Lee, R.J., Li, J., Callahan, J., Ftouni, S., Dhomen, N., Middlehurst, P., Wallace, A., Raleigh, J., Hatzimihalis, A., Henderson, M.A., Shackleton, M., Haydon, A., Mar, V., Gyorki, D.E., Oudit, D., Dawson, M.A., Hicks, R.J., Lorigan, P., McArthur, G.A., Marais, R., Wong, S.Q., Dawson, S.-J.

“…The advent of effective adjuvant therapies for patients with resected melanoma has highlighted the need to stratify patients based on risk of relapse given the…”
Get full text

Providing cancer surgery in the COVID‐19 crisis by Downs, J. S., Wilkinson, M. J., Gyorki, D. E., Speakman, D.

Get full text

Desmoplastic melanoma: a review of its pathology and clinical behaviour, and of management recommendations in published guidelines by Hughes, T.M., Williams, G.J., Gyorki, D.E., Kelly, J.W., Stretch, J.R., Varey, A.H.R., Hong, A.M., Scolyer, R.A., Thompson, J.F.

“…Desmoplastic melanomas are uncommon. Their behaviour differs from that of other melanoma subtypes; therefore, management guidelines for non‐desmoplastic…”
Get full text

Management of synchronous tumours of the oesophagus and pancreatic head: a novel approach by Gyorki, D E, Clarke, N E, Hii, M W, Banting, S W, Cade, R J

“…Synchronous tumours of the oesophagus and pancreatic head are very rare. This report describes a unique case of an adenocarcinoma of the distal oesophagus and…”
Get full text

Subungual melanoma: Management in the modern era by Reilly, D.J., Aksakal, G., Gilmour, R.F., Gyorki, D.E., Chauhan, A., Webb, A., Henderson, M.A.

“…Subungual melanoma is a rare subtype of cutaneous melanoma that arises from the structures of the nail apparatus. It presents most commonly in older patients…”
Get full text

Sentinel lymph node biopsy rates in Victoria, 2018 and 2019 by Watts, Caroline, Spillane, Andrew, Henderson, Michael A, Cust, Anne, Braithwaite, J, Gyorki, DE, Hong, AM, Kelly, JW, Long, GV, Mar, VJ, Menzies, AM, Morton, RL, Rapport, F, Saw, RPM, Schmid, H, Scolyer, RA, Smith, AL, Winder, A, Mann, GJ

Get full text

The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases: A multicenter cohort study by Olofsson Bagge, Roger, Holmberg, Carl Jacob, Hieken, Tina J., Zager, Jonathan S., Long, Georgina V., Van Akkooi, Alexander Christopher Jonathan, Karakousis, Giorgos C, Pallan, Lalit, Vetto, John T., Gyorki, David E., Ascierto, Paolo Antonio, Dummer, Reinhard, Hui, Jane Yuet Ching, Schachter, Jacob, Helgadottir, Hildur, Kroon, Hidde, Rothermel, Luke Daniel, Carlino, Matteo S., Broman, Kristy Kummerow, Ny, Lars

“…9569 Background: Guidelines addressing melanoma in-transit metastasis (ITM) recommend immune checkpoint inhibitors (ICI) as a first-line treatment option,…”
Get full text

Incidence and location of positive nonsentinel lymph nodes in head and neck melanoma by Gyorki, D.E, Boyle, J.O, Ganly, I, Morris, L, Shaha, A.R, Singh, B, Wong, R.J, Shah, J.P, Busam, K, Kraus, D, Coit, D.G, Patel, S

“…Abstract Background The complex lymphatic drainage in the head and neck makes sentinel lymph node biopsy (SLNB) for melanomas in this region challenging. This…”
Get full text

Knowledge and attitudes of Australian dermatologists towards sentinel lymph node biopsy for melanoma: a mixed methods study by Smith, Andrea L, Watts, Caroline G, Robinson, Samuel, Schmid, Helen, Goumas, Chris, Mar, Victoria J, Thompson, John F, Rapport, Frances, Cust, Anne E, Braithwaite, J, Gyorki, DE, Henderson, M, Hong, AM, Kelly, JW, Long, GV, Menzies, AM, Morton, RL, Saw, RPM, Scolyer, RA, Spillane, AJ, Mann, GJ

“…Background/Objectives In melanoma management, sentinel lymph node biopsy (SLNB) is used to stage patients and to indicate prognosis. More recently, it has been…”
Get full text

Enterocutaneous fistula: a single-centre experience by Gyorki, D. E., Brooks, C. E., Gett, R., Woods, R. J., Johnston, M., Keck, J. O., Mackay, J. R., Heriot, A. G.

“…Background:  Enterocutaneous fistulae (ECFs) present a difficult management problem and can cause significant morbidity. The aim of the study was to assess the…”
Get full text

CR12ENTEROCUTANEOUS FISTULAE - ARE WE GETTING IT RIGHT? by Gyorki, D. E., Brooks, C., Gett, R., Heriot, A. G.

“…Enterocutaneous fistulae (ECF) present a difficult management problem and can cause significant morbidity. The aim of the study was to assess the outcome of…”
Get full text

Desmoplastic melanoma: A pathologically and clinically distinct form of cutaneous melanoma B by Hawkins, W. G., Busam, K. J., BenPorat, L., Panageas, K., Coit, D. G., Gyorki, D. E., Linehan, D. C., Brady, M. S.

Get full text

Active surveillance of patients who have sentinel node positive melanoma: An international, multi‐institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT‐2) by Broman, Kristy Kummerow, Hughes, Tasha, Dossett, Lesly, Sun, James, Kirichenko, Dennis, Carr, Michael J., Sharma, Avinash, Bartlett, Edmund K., Nijhuis, Amanda A. G., Thompson, John F., Hieken, Tina J., Kottschade, Lisa, Downs, Jennifer, Gyorki, David E., Stahlie, Emma, Akkooi, Alexander, Ollila, David W., Frank, Jill, Song, Yun, Karakousis, Giorgos, Moncrieff, Marc, Nobes, Jenny, Vetto, John, Han, Dale, Farma, Jeffrey M., Deneve, Jeremiah L., Fleming, Martin D., Perez, Matthew C., Lowe, Michael C., Olofsson Bagge, Roger, Mattsson, Jan, Lee, Ann Y., Berman, Russell S., Chai, Harvey, Kroon, Hidde M., Teras, Juri, Teras, Roland M., Farrow, Norma E., Beasley, Georgia, Hui, Jane Yuet Ching, Been, Lukas, Kruijff, Schelto, Kim, Youngchul, Naqvi, Syeda Mahrukh Hussnain, Sarnaik, Amod A., Sondak, Vernon K., Zager, Jonathan S.

“…Background For patients with sentinel lymph node (SLN)‐positive cutaneous melanoma, the Second Multicenter Selective Lymphadenectomy trial demonstrated…”
Get full text

LBA66Primary 2-year (yr) results of a phase II, multicenter, randomized, open-label trial of efficacy and safety for talimogene laherparepvec (T-VEC) neoadjuvant (neo) treatment (tx) plus surgery (surg) vs surg in patients (pts) with resectable stage IIIB-IVM1a melanoma by Dummer, R, Gyorki, D E, Hyngstrom, J, Berger, A, Conry, R, Demidov, L, Sharma, A, Treichel, S A, Gorski, K, Anderson, A, Faries, M, Ross, M I

“…Abstract Background Risk of recurrence and death remain high for pts with advanced melanoma after resection. TVEC, an intralesional immunotherapy for advanced…”
Get full text

Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched Analysis by Broman, Kristy K., Hughes, Tasha M., Dossett, Lesly A., Sun, James, Carr, Michael J., Kirichenko, Dennis A., Sharma, Avinash, Bartlett, Edmund K., Nijhuis, Amanda AG, Thompson, John F., Hieken, Tina J., Kottschade, Lisa, Downs, Jennifer, Gyorki, David E., Stahlie, Emma, van Akkooi, Alexander, Ollila, David W., Frank, Jill, Song, Yun, Karakousis, Giorgos, Moncrieff, Marc, Nobes, Jenny, Vetto, John, Han, Dale, Farma, Jeffrey, Deneve, Jeremiah L., Fleming, Martin D., Perez, Matthew, Baecher, Kirsten, Lowe, Michael, Bagge, Roger Olofsson, Mattsson, Jan, Lee, Ann Y., Berman, Russell S., Chai, Harvey, Kroon, Hidde M., Teras, Roland M., Teras, Juri, Farrow, Norma E., Beasley, Georgia M., Hui, Jane YC, Been, Lukas, Kruijff, Schelto, Boulware, David, Sarnaik, Amod A., Sondak, Vernon K., Zager, Jonathan S.

“…In sentinel lymph node (SLN)-positive melanoma, two randomized trials demonstrated equivalent melanoma-specific survival with nodal surveillance vs completion…”
Get full text

Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC) (Jan, 10.1245/S10434-021-11236-Y, 2022) by van Akkooi, A. C. J., Hieken, T. J., Burton, E. M., Ariyan, C., Ascierto, P. A., Asero, Svma, Blank, C. U., Block, M. S., Boland, G. M., Caraco, C., Chng, S., Davidson, B. S., Neto, J. P. D., Faries, M. B., Gershenwald, J. E., Grunhagen, D. J., Gyorki, D. E., Han, D. L., Hayes, A. J., van Houdt, W. J., Karakousis, G. C., Klop, W. M. C., Long, G. V., Lowe, M. C., Menzies, A. M., Olofsson Bagge, Roger, Pennington, T. E., Rutkowski, P., Saw, R. P. M., Scolyer, R. A., Shannon, K. F., Sondak, V. K., Tawbi, H., Testori, A. A. E., Tetzlaff, M. T., Thompson, J. F., Zager, J. S., Zuur, C. L., Wargo, J. A., Spillane, A. J., Ross, M. I., Int Neoadjuvant Melanoma, Consortiu

Get full text

Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB–IVM1a melanoma: a randomized, open-label, phase 2 trial by Dummer, R., Gyorki, D. E., Hyngstrom, J., Berger, A. C., Conry, R., Demidov, L., Sharma, A., Treichel, S. A., Radcliffe, H., Gorski, K. S., Anderson, A., Chan, E., Faries, M., Ross, M. I.

Get full text